Personalis, Inc. $PSNL Stock Bought by Aberdeen Group plc

Aberdeen Group plc raised its holdings in shares of Personalis, Inc. (NASDAQ:PSNL) by 39.1% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,211,939 shares of the company’s stock after buying an additional 1,464,649 shares during the quarter. Aberdeen Group plc’s holdings in Personalis were worth $84,850,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of the business. Merck & Co. Inc. purchased a new position in shares of Personalis in the second quarter worth about $188,202,236. BlackRock Inc. purchased a new stake in Personalis during the 2nd quarter valued at about $94,905,000. Bank of America Corp DE purchased a new stake in Personalis during the 2nd quarter valued at about $24,395,000. AIGH Capital Management LLC acquired a new stake in Personalis in the 2nd quarter valued at about $22,981,000. Finally, Dimensional Fund Advisors LP raised its holdings in Personalis by 8.4% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,066,248 shares of the company’s stock valued at $6,791,000 after acquiring an additional 83,074 shares during the last quarter. 61.91% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Personalis

In other Personalis news, CMO Richard Chen sold 3,998 shares of the business’s stock in a transaction dated Friday, September 18th. The shares were sold at an average price of $16.22, for a total transaction of $64,847.56. Following the sale, the chief marketing officer directly owned 169,882 shares in the company, valued at $2,755,486.04. This represents a 2.30% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, SVP Stephen Moore sold 2,068 shares of the business’s stock in a transaction dated Friday, September 18th. The stock was sold at an average price of $16.22, for a total transaction of $33,542.96. Following the sale, the senior vice president owned 90,257 shares in the company, valued at $1,463,968.54. This trade represents a 2.24% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders sold 16,456 shares of company stock valued at $266,916. 4.20% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

PSNL has been the topic of a number of research reports. UBS Group lowered shares of Personalis from a “buy” rating to a “neutral” rating in a research note on Tuesday, October 6th. Craig Hallum lowered Personalis from a “buy” rating to a “hold” rating and set a $16.25 price target for the company. in a research report on Monday, August 24th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Personalis in a research report on Thursday, October 15th. Zacks Research upgraded Personalis from a “strong sell” rating to a “hold” rating in a research report on Monday, September 7th. Finally, Lake Street Capital cut Personalis from a “buy” rating to a “hold” rating and set a $16.25 target price for the company. in a report on Monday, July 20th. Two equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $15.29.

Personalis Stock Down 0.9%

Shares of PSNL traded down $0.15 during trading on Friday, reaching $15.71. 2,803,799 shares of the company traded hands, compared to its average volume of 2,199,010. The stock has a 50-day simple moving average of $16.08 and a 200-day simple moving average of $11.61. Personalis, Inc. has a twelve month low of $4.95 and a twelve month high of $18.89. The stock has a market cap of $1.70 billion, a PE ratio of -13.43 and a beta of 2.40.

Personalis (NASDAQ:PSNL) last issued its quarterly earnings data on Wednesday, November 4th. The company reported ($0.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.06). Personalis had a negative net margin of 147.74% and a negative return on equity of 49.53%. The firm had revenue of $25.60 million during the quarter, compared to analyst estimates of $21.54 million.

About Personalis

Personalis is a cancer genomics company that develops sequencing and data-analysis tools for cancer research and personalized cancer care. Its services support pharmaceutical and biotechnology companies, academic researchers, and clinicians studying cancer and evaluating treatments. The company’s offerings include NeXT Personal, a blood-based test designed to detect molecular residual disease and monitor cancer recurrence using circulating tumor DNA. Personalis also provides tumor profiling and immunogenomics services that analyze cancer-related genetic changes and features of the tumor immune environment.